Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 3(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05813288Phase 3Terminated

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

Role: lead

NCT05763121Phase 3Terminated

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

Role: lead

NCT06388889Phase 3Terminated

Phase III Long-Term Extension Study With Dexpramipexole

Role: lead

NCT05748600Phase 3Active Not Recruiting

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

Role: lead

NCT06533553Phase 2Active Not Recruiting

A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD

Role: lead

All 5 trials loaded